Oppenheimer analysts on Monday cut their target to 5950, about a 17% premium to Friday's close, from 7100. Read Investopedia's live coverage of today's trading here. "The equity market appears ...

Investment bank Oppenheimer cut its target price on Walmart to $95 per share, the lowest target tracked by Visible Alpha. The retailer could attract more shoppers stocking up on products ahead of ...

John Stoltzfus, Oppenheimer chief investment strategist, joins 'The Exchange' to discuss Wall Street's expectations for market performance this year, if price targets could fall further ...

On April 16, Oppenheimer will be back on Peacock after finishing its run on Prime Video. That’s the one of the best films of the decade, and it deserves to have a long run on Peacock.

But for now, the time to record those receipts is quickly running out. What better time then, to invite independent tax expert Geof Nightingale to the studio - he's a former partner at PwC and member ...

Goldman Sachs strategist Peter Oppenheimer reckons investors have broadly priced in an increase in America’s average tariff rate from between 2 per cent to 3 per cent to around 10 per cent.

Saxophonist and composer Geof Bradfield blends modern jazz, African rhythms, and the roots music of his native South into a style that is “explicitly adventurous and forward-looking” (AllAboutJazz.com ...

Robert Oppenheimer helped develop the atom bomb is reportedly working to return to earnest pit production. The U.S. has never imported plutonium pits but also hasn’t done any such major ...

The Ore Docks Brewing Co. was filled with something for everybody, from vinyl to CDs. Event organizers Geof Walker and Jon Teichman say it’s been a great show to start the year with. They say ...

With a few clicks, anyone can now create a ‘Ghiblified’ version of Oppenheimer, Sholay, or even Lionel Messi’s last match. Mehdi Saajid, a new media artist who dabbles in AI, views ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), with a price target of $4.00. The company’s ...